Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28115601 | 0.78 | NAALAD2 (0.38) | HMGCRCHRM1TBXA2RADRA1AHIF1A | |
| SCHEMBL3516359 | 0.71 | HMGCR (0.46) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL27656530 | 0.70 | — | — | |
| SCHEMBL15995099 | 0.67 | — | — | |
| SCHEMBL14876761 | 0.67 | — | — | |
| SCHEMBL17655761 | 0.67 | ALDH1A1 (0.30) | ALDH1A1 | |
| Citric Acid SCHEMBL28188885 | 0.65 | ALDH1A1 (0.62) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL5309982 | 0.65 | HMGCR (0.39) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL19520696 | 0.65 | — | — | |
| SCHEMBL8385130 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6414165-B1 | REACTING LOWER ALKYL ESTER OF 4,5-EPOXY-3,3-DIMETHYLPENTANOIC ACID OR SULFONIC ESTER OF BETA,BETA-DIMETHYL-GAMMA-(HYDROXYMETHYL)-GAMMA-BUTYROLACTONE WITH ALKALI METAL OR QUATERNARY AMMONIUM ALKOXIDE IN ETHER | SYNGENTA LIMITED (GB) | 2002-07-02 | — | — | US | claimed |
| EP-1080085-A1 | PREPARATION OF CIS-6,6-DIMETHYL-3-OXA-BICYCLO 3.1.0]HEXAN-2-ONE | ZENECA LIMITED (GB) | 2001-03-07 | — | — | EP | claimed |
| WO-1999054324-A1 | PREPARATION OF CIS-6,6-DIMETHYL-3-OXA-BICYCLO[3.1.0]HEXAN-2-ONE | ZENECA LIMITED (GB) | 1999-10-28 | — | — | WO | claimed |
| CN-117209463-A | Synthetic method of caronic anhydride | 浙江沙星科技股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| US-20020161244-A1 | Preparation of cis-6,6-dimethyl-3-oxa-bicyclo(3.1.0)hexan-2-one | LEVIN DANIEL (GB) | 2002-10-31 | — | — | US | disclosed |
| US-6414165-B1 | REACTING LOWER ALKYL ESTER OF 4,5-EPOXY-3,3-DIMETHYLPENTANOIC ACID OR SULFONIC ESTER OF BETA,BETA-DIMETHYL-GAMMA-(HYDROXYMETHYL)-GAMMA-BUTYROLACTONE WITH ALKALI METAL OR QUATERNARY AMMONIUM ALKOXIDE IN ETHER | SYNGENTA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| US-6414165-B1 | REACTING LOWER ALKYL ESTER OF 4,5-EPOXY-3,3-DIMETHYLPENTANOIC ACID OR SULFONIC ESTER OF BETA,BETA-DIMETHYL-GAMMA-(HYDROXYMETHYL)-GAMMA-BUTYROLACTONE WITH ALKALI METAL OR QUATERNARY AMMONIUM ALKOXIDE IN ETHER | SYNGENTA LIMITED (GB) | 2002-07-02 | — | — | US | disclosed |
| CN-1297446-A | Process for the preparation of cis-6, 6-dimethyl-3-oxo-bicyclo (3.1.0) hexan-2-one | ZENECA LTD (GB) | 2001-05-30 | — | — | CN | disclosed |
| EP-1080085-A1 | PREPARATION OF CIS-6,6-DIMETHYL-3-OXA-BICYCLO 3.1.0]HEXAN-2-ONE | ZENECA LIMITED (GB) | 2001-03-07 | — | — | EP | disclosed |
| EP-1080085-A1 | PREPARATION OF CIS-6,6-DIMETHYL-3-OXA-BICYCLO 3.1.0]HEXAN-2-ONE | ZENECA LIMITED (GB) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054324-A1 | PREPARATION OF CIS-6,6-DIMETHYL-3-OXA-BICYCLO[3.1.0]HEXAN-2-ONE | ZENECA LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |
| WO-1999054324-A1 | PREPARATION OF CIS-6,6-DIMETHYL-3-OXA-BICYCLO[3.1.0]HEXAN-2-ONE | ZENECA LIMITED (GB) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161244-A1 | Preparation of cis-6,6-dimethyl-3-oxa-bicyclo(3.1.0)hexan-2-one | MSMO1, CYP2B6, CYP2D6 | HMGCR 554/4885CHRM1 410/4885TBXA2R 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.